Immuni Phase News Today

IRVINE, Calif.--(BUSINESS WIRE)--May 22, 2024--

IRVINE, Calif.--(BUSINESS WIRE)--Feb 23, 2024--

IRVINE, Calif.--(BUSINESS WIRE)--Jan 11, 2024--

IRVINE, Calif.--(BUSINESS WIRE)--Dec 20, 2023--

IRVINE, Calif.--(BUSINESS WIRE)--#ClinicalTrials--Immunis, Inc., a leading biotechnology company forging innovative cellular secretome therapies for age and disease-related immune decline, is delighted to announce that its Chief Business Officer, Mark Cabato, will be a keynote speaker at this year's Drug Discovery S...

IRVINE, Calif.--(BUSINESS WIRE)--#ClinicalTrials--Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, is pleased to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Innovative Therapies Days confere...

IRVINE, Calif., October 09, 2023--Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, is pleased to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Innovative Therapies Days conference in Besançon, France. Innovative Therapies Days is a premier event in medical innovation, showcasing presentations from esteemed clinicians, scientists, and industry partners. This year, the ...

Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, is pleased to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at

IRVINE, Calif.--(BUSINESS WIRE)--Aug 21, 2023--

IRVINE, Calif.--(BUSINESS WIRE)--#ClinicalTrials--Immunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the "Best Emerging Technology Company" by the Octane High Tech Awards (HTA). The HTA award...